Sirona Biochem (Seite 3102)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 04.06.24 09:05:21 von
neuester Beitrag 04.06.24 09:05:21 von
Beiträge: 31.077
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 1
Gesamt: 5.409.950
Gesamt: 5.409.950
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0350
EUR
+4,48 %
+0,0015 EUR
Letzter Kurs 05.06.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9380 | +68,98 | |
| 1,5000 | +50,00 | |
| 0,6190 | +43,95 | |
| 3,3800 | +34,66 | |
| 5,7900 | +24,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,4000 | -28,95 | |
| 0,9500 | -43,11 | |
| 1,2000 | -46,67 | |
| 0,5557 | -50,45 | |
| 2,0400 | -58,87 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sirona Biochem Appoints Nigel Terrett to Board of Directors
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 28, 2013) - November 28, 2013 - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announced today the appointment of Nigel Terrett to its Board of Directors.
"We are thrilled that Nigel Terrett has agreed to join the team," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "Nigel's background in implementing successful strategic plans in life sciences, and his existing in-depth knowledge of Sirona through his work as our Strategic Advisor, will be an asset to us as we move forward in the growth and expansion of our business."
Sirona Biochem also announces that Chris Verrico will be stepping down from the company's Board of Directors. The company would like to extend its thanks and gratitude for his contribution.
About Nigel Terrett
Nigel Terrett has held many leadership roles in the life sciences sector some of which include his role of Chief Strategic Officer of LifeLabs Inc., Chairman of the Board at Excelleris Technologies, Senior Vice President of MDS Diagnostics Inc., and CIO within MDS Health Group. More recently, Nigel has provided strategic advisory services to the Biotech industry.
Read more at http://www.stockhouse.com/news/press-releases/2013/11/28/sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 28, 2013) - November 28, 2013 - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announced today the appointment of Nigel Terrett to its Board of Directors.
"We are thrilled that Nigel Terrett has agreed to join the team," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "Nigel's background in implementing successful strategic plans in life sciences, and his existing in-depth knowledge of Sirona through his work as our Strategic Advisor, will be an asset to us as we move forward in the growth and expansion of our business."
Sirona Biochem also announces that Chris Verrico will be stepping down from the company's Board of Directors. The company would like to extend its thanks and gratitude for his contribution.
About Nigel Terrett
Nigel Terrett has held many leadership roles in the life sciences sector some of which include his role of Chief Strategic Officer of LifeLabs Inc., Chairman of the Board at Excelleris Technologies, Senior Vice President of MDS Diagnostics Inc., and CIO within MDS Health Group. More recently, Nigel has provided strategic advisory services to the Biotech industry.
Read more at http://www.stockhouse.com/news/press-releases/2013/11/28/sir…
Sirona Grants Stock Options
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 22, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) (the "Company") announces that it has granted, under its stock option plan, incentive stock options to directors, officers and consultants for the purchase of up to 2,150,000 common shares of the Company at a price of $0.15 per share for a period of five years.
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at http://www.stockhouse.com/news/press-releases/2013/11/22/sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 22, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) (the "Company") announces that it has granted, under its stock option plan, incentive stock options to directors, officers and consultants for the purchase of up to 2,150,000 common shares of the Company at a price of $0.15 per share for a period of five years.
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at http://www.stockhouse.com/news/press-releases/2013/11/22/sir…
Antwort auf Beitrag Nr.: 45.630.301 von Jon_Schnee am 15.10.13 14:29:12wow. Company plannt in den nächsten 2.5 Jahre 30 neue Mitarbeiter im Labor von Frankreich einzustelen. Derzeit sind es 8 Mitarbeiter in Frankreich (Labor) und 8 in Kanada (Management, Finanzen, PR, etc...)
Dierve LOI Verträge sind abgeschlossen. Aber noch kein Fixer Vertrag.
Und Sirona drückt jetzt richtig auf Tempo mit der Entwicklung von neuen Compounds. Nicht ganz Risikoarm das ganze Unterfangen, doch bis jetzt Überzeugt mich das Management sehr.
Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.
Dierve LOI Verträge sind abgeschlossen. Aber noch kein Fixer Vertrag.
Und Sirona drückt jetzt richtig auf Tempo mit der Entwicklung von neuen Compounds. Nicht ganz Risikoarm das ganze Unterfangen, doch bis jetzt Überzeugt mich das Management sehr.
Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.
Sirona Biochem Corporation-CEO's Report on Progress
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 15, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) today provided a business update.
I'd like to take this opportunity to summarize Sirona Biochem's business and strategic growth over the past 12 months.
Financial
In October 2012, Sirona Biochem's share price hit a low of 4 cents and our market cap was $3 million CDN. We made the decision to raise money using a debt instrument to avoid a punitive equity financing. We raised $600,000 in debt which gave us the financial runway to grow the value of the company to a high of 14 cents per share and a market cap of more than $11 million on January 18th 2013.
February 22, 2013 we announced an equity financing target of $2.7 million and we closed the second tranche of this financing on April 30, 2013 having raised $1.8 million in equity.
September 11, 2013 we announced an equity financing target of $1 million and we oversubscribed the private placement, closing on September 19th having raised $1.17 million.
On October 11, 2013, Sirona's share price was 16.5 cents and our market cap was $17.83 million CDN, representing an increase in market capitalization of $14,644,394.00 CDN and a market capitalization increase of 560%.
As of October 11, 2013, Sirona Biochem's running 3 month average trading volume was in excess of 500,000 shares per day.
Strategy
The decision was made in November 2012 that we would de-risk our business model and simplify our operations.
Sirona' Biochem's business model:
Sirona Biochem's expertise is in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return for the licenses, Sirona will receive licensing fees, milestone payments and ongoing royalty payments. The more compounds Sirona Biochem creates, the more revenue streams Sirona Biochem receives.
With this level of strategic focus, we diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.
Operations
In November 2012 we restructured the company and downsized our corporate head office by one position. In our laboratory in France we assessed every project in development and made the decision to focus our resources on two projects (SGLT2 inhibitor and skin lightening) to ensure each would be completed and available for transaction within 6 months. All other projects were assigned a timeline for re-insertion into the development pipeline contingent upon the successful completion of our two prioritized projects.
Business Development
In the last 12 months we have attended / presented at the following meetings, conferences and events:
•In Cosmetics Asia (Thailand)
•In Cosmetics Europe (France)
•Bio Partnering North America (Vancouver)
•BioPharm America (Boston)
•BIO International Convention (Chicago)
•BIOTECanada CEO Summit (Chicago)
•BioInvestor Forum (San Francisco)
•Beijing, Tianjin, Guangzhou, Shanghai, China (2 trips - business development and investor relations)
•Paris, Rouen, France (5 trips - business development and management of TFChem)
•New York, USA (4 trips - investor relations and setting up strategic relationships)
•Tokyo, Yokohama, Japan (business development)
•California, USA (3 trips - business development and investor relations)
•Toronto, Canada (business development and investor relations)
•London, UK (Cosmetic Business Innovation Awards - Sirona Biochem's skin lightening compound was a finalist in the Innovation in Ingredients category, competing against Dow Chemical, Dove Spa, Mibelle Biochemistry and Seppic)
Our process for maximizing the potential value of our compounds is as follows: we connect with as many pharmaceutical, biotech, cosmetic and consumer health companies as possible that may have interest in our technology. Starting all of these discussions in parallel enables us to move the conversations forward within a predictable window of opportunity. These concurrent conversations create a competitive environment for our technology, maximizing its value within the marketplace.
Summary:
As a result of our international team's efforts, in the last 7 months Sirona Biochem has announced the following:
•Material Transfer Agreement with VitamFero, a member of Genopole, for testing of our biological preservation technology in combination with their live attenuated animal vaccines.
•Letter of Intent (LOI) with Biogalenys to develop preclinical data supporting multiple applications of Sirona Biochem's glycoprotein (cell preservation technology).
•Letter of Intent (LOI) with Cincinnati Children's Hospital Medical Center, the #3 ranked hospital among all honor roll hospitals in the USA. The goal of our collaboration is to combine our proprietary technologies to create a novel skin care technology which will be commercialized by a global leader in cosmetic or consumer packaged goods sales.
•Letter of Intent (LOI) with Wanbang Pharma, China's number one ranked anti-diabetic company. Wanbang Pharma will receive an exclusive license for sales of Sirona Biochem's SGLT2 Inhibitor in the People's Republic of China in return for licensing and clinical milestone fees and ongoing royalty payments. Wanbang Pharma will be responsible for funding all clinical studies and development of the SGLT2 Inhibitor and Sirona Biochem will receive all of the data generated by Wanbang Pharma with the goal of exponentially raising the value of Sirona Biochem's SGLT2 Inhibitor for licensing agreements throughout the rest of the world.
•Letter of Intent (LOI) with Obagi Medical Products for a global exclusive license of Sirona Biochem's skin lightening compound TFC-849. Obagi Medical Products will be responsible for all development, manufacturing and sales of the compound and in return Sirona Biochem will receive licensing and milestone fees and ongoing royalty payments.
•Letter of Intent (LOI) to create a joint venture with Bloom Burton and Co., Canada's largest and most active healthcare-specialized investment banking group. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Moving forward we are strategically and operationally optimized to transition Sirona Biochem to its next phase of growth. Our short term focus is to formalize each of the LOIs that we have signed, confirming Sirona Biochem's first commercial transactions and predictable revenue streams. These formal agreements will mark the final transition from our being a research and development operation to a revenue generating business with globally recognized and respected brands as our partners.
Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.
Our overarching goal is for Sirona Biochem to become recognized as a global leader in the discovery of new products for leading cosmetic and pharmaceutical brands. Continued success creating commercially innovative and lucrative products for global brands will make Sirona Biochem a prized resource for the world's largest companies.
Best Regards,
Neil Belenkie, CEO
Sirona Biochem
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 15, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) today provided a business update.
I'd like to take this opportunity to summarize Sirona Biochem's business and strategic growth over the past 12 months.
Financial
In October 2012, Sirona Biochem's share price hit a low of 4 cents and our market cap was $3 million CDN. We made the decision to raise money using a debt instrument to avoid a punitive equity financing. We raised $600,000 in debt which gave us the financial runway to grow the value of the company to a high of 14 cents per share and a market cap of more than $11 million on January 18th 2013.
February 22, 2013 we announced an equity financing target of $2.7 million and we closed the second tranche of this financing on April 30, 2013 having raised $1.8 million in equity.
September 11, 2013 we announced an equity financing target of $1 million and we oversubscribed the private placement, closing on September 19th having raised $1.17 million.
On October 11, 2013, Sirona's share price was 16.5 cents and our market cap was $17.83 million CDN, representing an increase in market capitalization of $14,644,394.00 CDN and a market capitalization increase of 560%.
As of October 11, 2013, Sirona Biochem's running 3 month average trading volume was in excess of 500,000 shares per day.
Strategy
The decision was made in November 2012 that we would de-risk our business model and simplify our operations.
Sirona' Biochem's business model:
Sirona Biochem's expertise is in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return for the licenses, Sirona will receive licensing fees, milestone payments and ongoing royalty payments. The more compounds Sirona Biochem creates, the more revenue streams Sirona Biochem receives.
With this level of strategic focus, we diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.
Operations
In November 2012 we restructured the company and downsized our corporate head office by one position. In our laboratory in France we assessed every project in development and made the decision to focus our resources on two projects (SGLT2 inhibitor and skin lightening) to ensure each would be completed and available for transaction within 6 months. All other projects were assigned a timeline for re-insertion into the development pipeline contingent upon the successful completion of our two prioritized projects.
Business Development
In the last 12 months we have attended / presented at the following meetings, conferences and events:
•In Cosmetics Asia (Thailand)
•In Cosmetics Europe (France)
•Bio Partnering North America (Vancouver)
•BioPharm America (Boston)
•BIO International Convention (Chicago)
•BIOTECanada CEO Summit (Chicago)
•BioInvestor Forum (San Francisco)
•Beijing, Tianjin, Guangzhou, Shanghai, China (2 trips - business development and investor relations)
•Paris, Rouen, France (5 trips - business development and management of TFChem)
•New York, USA (4 trips - investor relations and setting up strategic relationships)
•Tokyo, Yokohama, Japan (business development)
•California, USA (3 trips - business development and investor relations)
•Toronto, Canada (business development and investor relations)
•London, UK (Cosmetic Business Innovation Awards - Sirona Biochem's skin lightening compound was a finalist in the Innovation in Ingredients category, competing against Dow Chemical, Dove Spa, Mibelle Biochemistry and Seppic)
Our process for maximizing the potential value of our compounds is as follows: we connect with as many pharmaceutical, biotech, cosmetic and consumer health companies as possible that may have interest in our technology. Starting all of these discussions in parallel enables us to move the conversations forward within a predictable window of opportunity. These concurrent conversations create a competitive environment for our technology, maximizing its value within the marketplace.
Summary:
As a result of our international team's efforts, in the last 7 months Sirona Biochem has announced the following:
•Material Transfer Agreement with VitamFero, a member of Genopole, for testing of our biological preservation technology in combination with their live attenuated animal vaccines.
•Letter of Intent (LOI) with Biogalenys to develop preclinical data supporting multiple applications of Sirona Biochem's glycoprotein (cell preservation technology).
•Letter of Intent (LOI) with Cincinnati Children's Hospital Medical Center, the #3 ranked hospital among all honor roll hospitals in the USA. The goal of our collaboration is to combine our proprietary technologies to create a novel skin care technology which will be commercialized by a global leader in cosmetic or consumer packaged goods sales.
•Letter of Intent (LOI) with Wanbang Pharma, China's number one ranked anti-diabetic company. Wanbang Pharma will receive an exclusive license for sales of Sirona Biochem's SGLT2 Inhibitor in the People's Republic of China in return for licensing and clinical milestone fees and ongoing royalty payments. Wanbang Pharma will be responsible for funding all clinical studies and development of the SGLT2 Inhibitor and Sirona Biochem will receive all of the data generated by Wanbang Pharma with the goal of exponentially raising the value of Sirona Biochem's SGLT2 Inhibitor for licensing agreements throughout the rest of the world.
•Letter of Intent (LOI) with Obagi Medical Products for a global exclusive license of Sirona Biochem's skin lightening compound TFC-849. Obagi Medical Products will be responsible for all development, manufacturing and sales of the compound and in return Sirona Biochem will receive licensing and milestone fees and ongoing royalty payments.
•Letter of Intent (LOI) to create a joint venture with Bloom Burton and Co., Canada's largest and most active healthcare-specialized investment banking group. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Moving forward we are strategically and operationally optimized to transition Sirona Biochem to its next phase of growth. Our short term focus is to formalize each of the LOIs that we have signed, confirming Sirona Biochem's first commercial transactions and predictable revenue streams. These formal agreements will mark the final transition from our being a research and development operation to a revenue generating business with globally recognized and respected brands as our partners.
Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.
Our overarching goal is for Sirona Biochem to become recognized as a global leader in the discovery of new products for leading cosmetic and pharmaceutical brands. Continued success creating commercially innovative and lucrative products for global brands will make Sirona Biochem a prized resource for the world's largest companies.
Best Regards,
Neil Belenkie, CEO
Sirona Biochem
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Die Kanadier haben uns Entdeckt 
Another board talks about Sirona Biochem
http://www.wallstreet-online.de/diskussion/1183167-51-60/sirona-biochem
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…...
Another board talks about Sirona Biochem
http://www.wallstreet-online.de/diskussion/1183167-51-60/sirona-biochem
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…...
Trading Spotlight
Schon erstaunlich das hier niemand schreibt... ist jemand investiert?
Denke wir werden hier noch sehr viel Spass haben
Denke wir werden hier noch sehr viel Spass haben
NEWS - und weiter geht's
Sirona Biochem Announces LOI for Collaboration With Bloom Burton & Co.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 8, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a Letter of Intent to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Leveraging Sirona's proprietary fluorination technology platform, Sirona and Bloom Burton will identify and design promising assets, undertake chemical synthesis and scale up, and conduct preclinical proof of concept studies necessary to support further development activities. The collaboration hopes to address rare or neglected inflammatory diseases and the threat of emerging bacterial resistance, both of which are markets with enormous medical need. Sirona and Bloom Burton will share in the future proceeds arising from the commercialization activities.
"Bloom Burton is Canada's leading healthcare-specialized investment banking group," said Neil Belenkie, CEO of Sirona Biochem. "We are proud to be developing a collaborative partnership, where our joint expertise will be combined to develop and transact cutting-edge industry solutions in areas with unmet needs."
"One of Bloom Burton's many advantages is that we see the widest range of opportunities spanning early to late stage assets, at private and public companies across all areas of healthcare," said Bloom Burton President, Brian Bloom. "Through this experience, we understand where needs exist in the marketplace and what investors are seeking. We believe Sirona has an excess of therapeutic opportunities than can be exploited by Sirona alone. We are excited to develop these assets in partnership with Sirona and monetize them at the appropriate time."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at
http://www.stockhouse.com/News/Press-Releases/2013/10/08/Sir…
Sirona Biochem Announces LOI for Collaboration With Bloom Burton & Co.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 8, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a Letter of Intent to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Leveraging Sirona's proprietary fluorination technology platform, Sirona and Bloom Burton will identify and design promising assets, undertake chemical synthesis and scale up, and conduct preclinical proof of concept studies necessary to support further development activities. The collaboration hopes to address rare or neglected inflammatory diseases and the threat of emerging bacterial resistance, both of which are markets with enormous medical need. Sirona and Bloom Burton will share in the future proceeds arising from the commercialization activities.
"Bloom Burton is Canada's leading healthcare-specialized investment banking group," said Neil Belenkie, CEO of Sirona Biochem. "We are proud to be developing a collaborative partnership, where our joint expertise will be combined to develop and transact cutting-edge industry solutions in areas with unmet needs."
"One of Bloom Burton's many advantages is that we see the widest range of opportunities spanning early to late stage assets, at private and public companies across all areas of healthcare," said Bloom Burton President, Brian Bloom. "Through this experience, we understand where needs exist in the marketplace and what investors are seeking. We believe Sirona has an excess of therapeutic opportunities than can be exploited by Sirona alone. We are excited to develop these assets in partnership with Sirona and monetize them at the appropriate time."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at
http://www.stockhouse.com/News/Press-Releases/2013/10/08/Sir…
RE:Any Updates on This?
When I last discussed it with the company, the canncer vaccine was shelved to focus on the SLGT2 inhiitor and the skin lighteners, and to progress the "anti-aging" program on an opportunistic basis. The rationale was that the vaccine would take far more resources and time to develop than the priority programs. Trying to do so wuld have killed the company. I think that's what Neil means when he talks about the ability of a company to execute.
There are a number of companies out there that are or were involved with cancer vaccines. They haven't been as effective as theory suggests they should be because of how cancers also prevent activation of part of the immune system in their vicinity. Over the last few years, the issue has become better understood and ways have been developed to deal with it. I think we will see a resurgance of cancer vaccine trials going forward, using both the vaccine and adjuncts to manage the activation of the immune response. A competing approach is to skip the vaccine and just make a synthetic antibody to the overexpressed glycans, in which case Sirona's tech would not be as useful. I don't know which approach will eventually show more promise, so I can't say if Sirona's tech will be applicable in oncology.
If glycan'd antigens do prove useful as vaccines, then the stability of any glycosylation in the antigens will be an important issue. When I reviewed Sirona's patents, I wasn't looking for their applicability to vaccines. In any case, Sirona does not have a patent on fluorination of carbohydrates: they have patents on a particular way of doing it and on particular molecular structures. Other companies could fluorinate carbohydrates if they can figure out how to do it with the kind of control and specificity that TFChem's method has (e.g., replacing just the ester O with F). I doubt we'll see that anytime soon.
FWIW, here is a link to a nice site for a layperson to get a better understanding of glycosylation and carbohydrate biology:
http://www.glycoforum.gr.jp/glycoe/index.html It touches all the bases and provides definitions and links to more advance coverage of each topic.
If you have nothing else to do with your time and you want to search through an indepth textbook on the subject, try
http://www.ncbi.nlm.nih.gov/books/NBK1908/
I'm not well versed in the field, so I find both of these references useful at times.
Read more at
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
When I last discussed it with the company, the canncer vaccine was shelved to focus on the SLGT2 inhiitor and the skin lighteners, and to progress the "anti-aging" program on an opportunistic basis. The rationale was that the vaccine would take far more resources and time to develop than the priority programs. Trying to do so wuld have killed the company. I think that's what Neil means when he talks about the ability of a company to execute.
There are a number of companies out there that are or were involved with cancer vaccines. They haven't been as effective as theory suggests they should be because of how cancers also prevent activation of part of the immune system in their vicinity. Over the last few years, the issue has become better understood and ways have been developed to deal with it. I think we will see a resurgance of cancer vaccine trials going forward, using both the vaccine and adjuncts to manage the activation of the immune response. A competing approach is to skip the vaccine and just make a synthetic antibody to the overexpressed glycans, in which case Sirona's tech would not be as useful. I don't know which approach will eventually show more promise, so I can't say if Sirona's tech will be applicable in oncology.
If glycan'd antigens do prove useful as vaccines, then the stability of any glycosylation in the antigens will be an important issue. When I reviewed Sirona's patents, I wasn't looking for their applicability to vaccines. In any case, Sirona does not have a patent on fluorination of carbohydrates: they have patents on a particular way of doing it and on particular molecular structures. Other companies could fluorinate carbohydrates if they can figure out how to do it with the kind of control and specificity that TFChem's method has (e.g., replacing just the ester O with F). I doubt we'll see that anytime soon.
FWIW, here is a link to a nice site for a layperson to get a better understanding of glycosylation and carbohydrate biology:
http://www.glycoforum.gr.jp/glycoe/index.html It touches all the bases and provides definitions and links to more advance coverage of each topic.
If you have nothing else to do with your time and you want to search through an indepth textbook on the subject, try
http://www.ncbi.nlm.nih.gov/books/NBK1908/
I'm not well versed in the field, so I find both of these references useful at times.
Read more at
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
Antwort auf Beitrag Nr.: 45.544.071 von Jon_Schnee am 01.10.13 07:51:16Reply from Anatonia (Sirona Biochem)
Hi Marc, Thanks for your message. I am sorry to hear that you believe that shareholders are disappointed. We are very excited about the news with Obagi. It is a leading skincare company, with a global reach that was recently acquired by $35 billion company, Valeant Pharmaceuticals. Because the skin lightening TFC-849 compound is part of the cosmeceuticals market, it will not have to go through any regulatory hoops prior to hitting the shelves. Our negotiations with Obagi have gone smoothly and quickly, so we hope to see the firm licensing deal shortly. Because we are transparent in our business, we release news as soon as it is material, LOIs included. This allows us to show the steps that we are taking in our business strategy toward our goals, and to highlight the high level of interest that exists in our science. We have not one, but two fantastic licensing deals to look forward to so far, with our diabetes SGLT2 inhibitor and one of our skin lightening compounds. We are at a tipping point in our evolution from an R&D facility to a revenue generating business. This is an exciting time for Sirona shareholders. We are confident in our approach and are optimistically looking forward. I hope this helps!
Feel free to contact me any time. Best Regards, Antonia Issa, BA, MBA Communications Manager aissa@sironabiochem.com D 604.282.6065 Sirona Biochem Corp. 605-889 West Pender Street Vancouver, BC V6C 3B2 M 604.641.4466 F 604.608.5471 TF 1.888.SIRONA1 (7476221) TSX-V: SBM www.sironabiochem.com
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
Hi Marc, Thanks for your message. I am sorry to hear that you believe that shareholders are disappointed. We are very excited about the news with Obagi. It is a leading skincare company, with a global reach that was recently acquired by $35 billion company, Valeant Pharmaceuticals. Because the skin lightening TFC-849 compound is part of the cosmeceuticals market, it will not have to go through any regulatory hoops prior to hitting the shelves. Our negotiations with Obagi have gone smoothly and quickly, so we hope to see the firm licensing deal shortly. Because we are transparent in our business, we release news as soon as it is material, LOIs included. This allows us to show the steps that we are taking in our business strategy toward our goals, and to highlight the high level of interest that exists in our science. We have not one, but two fantastic licensing deals to look forward to so far, with our diabetes SGLT2 inhibitor and one of our skin lightening compounds. We are at a tipping point in our evolution from an R&D facility to a revenue generating business. This is an exciting time for Sirona shareholders. We are confident in our approach and are optimistically looking forward. I hope this helps!
Feel free to contact me any time. Best Regards, Antonia Issa, BA, MBA Communications Manager aissa@sironabiochem.com D 604.282.6065 Sirona Biochem Corp. 605-889 West Pender Street Vancouver, BC V6C 3B2 M 604.641.4466 F 604.608.5471 TF 1.888.SIRONA1 (7476221) TSX-V: SBM www.sironabiochem.com
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
Antwort auf Beitrag Nr.: 45.541.933 von Jon_Schnee am 30.09.13 18:42:29Wie schon erwähnt waren die Erwartungen hoch für den Skin-Whitening Deal. Viele erwarten einen grossen Namen wie L'Oreal etc... Nun ist es eine kleine Cosmetic Firma, die von einem mittelgrossen Pharmakonzern bald geschluckt wird. Na ja...
Durchsuchen
Sirona Biochem
